Every 10-Q that Petvivo Hldgs Inc (PETV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PETV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PETV filings page.
PetVivo Holdings, Inc. reported unaudited results for the three months ended June 30, 2026. Revenue was $337,572, up from $297,500 a year earlier, driven largely by distributor Vedco, which accounted for about 70% of sales, and Clipper, at about 12%.
Gross profit was $223,317. Operating expenses were $1,832,166, leading to an operating loss of $1,608,849 and a net loss of $1,613,888, an improvement versus a $2,311,037 net loss in the prior-year quarter. Net cash used in operating activities was $965,779. Cash declined to $122,633 and total assets to $2,669,481, with stockholders’ equity of $1,356,169 and an accumulated deficit of $103,051,394.
The company corrected prior accounting for a June 30, 2025 convertible note amendment by removing a $763,259 beneficial conversion feature in line with ASU 2020‑06; this changed equity classifications but did not affect prior revenue or net loss. Management concluded that recent losses, low cash, and dependence on external financing raise substantial doubt about the ability to continue as a going concern. Subsequent events include additional non-convertible debt financing and formal termination of the VetStem PrecisePRP licensing agreement.
PetVivo Holdings, Inc. reported another loss-making quarter for the period ended December 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern. Quarterly revenue fell to $286,108 from $583,313 a year earlier, while the net loss available to common stockholders widened to $2,316,455. For the nine months, revenue was $886,892 versus $907,783, with a net loss of $7,788,904. Cash dropped to just $18,164, against an accumulated deficit of $98,987,394. The company shifted away from prior distributors, now relying heavily on Vedco for most sales, and added new licensing agreements for PrecisePRP and an AI platform that it expects to drive future revenue.
PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.
Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).
The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.